Suchergebnisse - "Uchino, Junji"

PubPharm (18)

1

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer : A multicenter, Phase II trial

enthalten in: Cancer medicine | 2023

von Iwasaku, M. | Uchino, J. | Chibana, K. | +16

2

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients : The SPIRAL-0 Study

enthalten in: The oncologist | 2022

von Chihara, Y. | Takeda, T. | Goto, Y. | +20

ErratumIn: Oncologist. 2024 Mar 18;:. - PMID 38498842

3

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer

enthalten in: Cancer letters | 2021

von Tanimura, K. | Yamada, T. | Horinaka, M. | +13

4

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Okura, N. | Nishioka, N. | Yamada, T. | +19

5

Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)

enthalten in: Clinical lung cancer | 2019

von Hiranuma, O. | Uchino, J. | Yamada, T. | +5

6

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment : A Phase II Trial

enthalten in: The oncologist | 2019

von Nakao, A. | Hiranuma, O. | Uchino, J. | +26

7

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer

enthalten in: Cancer medicine | 2019

von Yamada, T. | Hirai, S. | Katayama, Y. | +14

8

Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis

enthalten in: Thoracic cancer | 2019

von Yoshimura, A. | Yamada, T. | Tsuji, T. | +7

9

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

enthalten in: Nature communications | 2019

von Taniguchi, H. | Yamada, T. | Wang, R. | +21

10

A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Imai, H. | Kaira, K. | Suzuki, K. | +11